3.3. M Stage, pT Category and Clark Level Are Significant and Independent Determinants of Tumor Response to BRAF + MEK Inhibitor Treatment in Patients with Metastatic Melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.